Opinion|Videos|May 17, 2024
Unmet Needs and Future Perspectives on the Treatment of EGFR-Mutated NSCLC
The expert panel concludes with thoughts on unmet needs and future perspectives on the treatment of patients with EGFR-mutated non–small cell lung cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Findings may provide reassurance to patients with early-stage disease that surgery may help improve survival rates.
Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.
Matthew Lee, MD, discusses the first clinical data for BG-C477, a CEACAM5-targeting ADC, in advanced NSCLC.
Matthew Lee, MD, shares his key takeaway from the first disclosure of BG-C477 data in advanced NSCLC.
Matthew Lee, MD, discusses how confident he is that CEACAM5 expression will hold up as a biomarker for BG-C477 in NSCLC.
In the real-world CEMI-LUNG study, first-line cemiplimab produced survival and response outcomes consistent with the pivotal EMPOWER-Lung 1 trial.
Data from the phase 3 OptiTROP-Lung06 trial may support sacituzumab tirumotecan plus pembrolizumab as a new frontline option for this NSCLC population.
Advertisement
Advertisement
Trending on CancerNetwork
1
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
2
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
3
Tambiciclib Combo Shows Activity in Relapsed/Refractory Post-Venetoclax AML
4
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
5